STERIS plc

STERIS plc

STE
STERIS plcUS flagNew York Stock Exchange
233.28
USD
-2.79
- -
22.73BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
27.51
31.14
31.67
30.57
30.81
32.9
35.75
36.47
43.3
45.5
52.02
55.37
60.45
61.58
Basic EPS, GAAP
2.2
2.27
1.57
1.29
3.42
3.59
4.81
4.66
2.5
1.07
3.83
6.23
7.97
8.21
Free Cash Flow per Basic Share
2.09
2.71
1.81
2.94
3.44
4.14
4.44
5.29
4.07
3.96
6.21
7.89
9.9
9.44
Dividend per Share
0.82
0.9
0.92
1.09
1.21
1.33
1.45
1.57
1.67
1.84
2.03
2.23
2.46
2.52
Book Value per Share
17.61
17.96
35.18
32.94
37.83
37.6
40.1
45.47
65.28
61.62
63.73
67.18
73.45
73.95
Tangible Book Value per Share
4.93
3.54
-2.99
-1.86
0.53
2.96
5.7
-0.51
-12
1.23
1.13
6.65
14
14.92
Basic Weighted Avg Shares
59
59
71
85
85
85
85
85
98
100
99
99
98
98
Sales/Revenue/Turnover
1,622
1,850
2,239
2,613
2,620
2,782
3,031
3,108
4,223
4,536
5,139
5,460
5,936
6,038
Operating Margin (%)
13.56
12.26
9.47
10.9
15.27
15.89
17.74
17.55
11.31
17.45
16.78
17.6
18.63
18.95
Depreciation Expense
76
92
144
188
178
226
197
219
553
553
565
476
486
491
Net Income, GAAP
129
135
111
110
291
304
408
397
244
107
378
615
782
805
Effective Tax Rate (%)
31.29
35.32
35.08
40.08
17.85
17.42
18.22
23.32
22.45
18.24
21.27
23.2
25.04
25.79
Profit Margin (%)
7.98
7.3
4.95
4.21
11.1
10.92
13.45
12.79
5.77
2.36
7.36
11.26
13.18
13.33
Working Capital
420
437
572
636
591
589
720
634
957
1,150
1,938
979
1,250
1,162
LT Debt
493
621
1,568
1,478
1,316
1,183
1,265
1,780
3,101
3,158
3,266
2,043
1,932
1,766
Total Equity
1,041
1,074
3,039
2,810
3,217
3,186
3,418
3,891
6,545
6,087
6,315
6,616
7,197
7,221
Return on Invested Capital (%)
10.24
9.12
4.37
3.83
7.46
8.21
9.69
8.03
4.77
6.75
7.13
7.98
9.16
9.23
Return on Capital (%)
9.57
9.13
4.37
3.06
7.52
7.64
9.71
8.2
4.05
2.08
5.15
7.34
9.11
9.25
Return on Common Equity (%)
13.05
12.8
5.41
3.78
9.69
9.52
12.38
10.91
4.68
1.7
6.11
9.53
11.35
11.37

Capital Structure

FRC

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
34
155
279
LT Borrowings
1,898
1,813
1,650
LT Finance Leases
121
120
115
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
98
98
97
Market Capitalization
24,882
21,627
20,522

Working Capital

FRC

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
2,286
2,395
2,446
Cash, Cash Equivalents & STI
424
440
482
Accounts Receivable, Net
991
1,093
1,013
Inventories
674
632
712
Total Current Liabilities
922
1,145
1,283
Payables & Accruals
406
424
497
ST Debt
34
155
279
Deferred Revenue
59
59
61

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.56%
15.7%
8.79%
Free Cash Flow
25.39%
18.95%
24.99%
Net Income, GAAP
44.84%
49.69%
27.27%
Sales/Revenue/Turnover
10.62%
14.31%
8.73%
Total Cash Common Dividend
14.41%
12.66%
9.96%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,280
1,329
1,370
1,481
5,460
2026
1,391
1,460
1,496
1,588
5,936
2027
1,493
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.47
1.52
1.76
1.48
6.23
2026
1.8
1.95
1.96
2.25
7.97
2027
2.05
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.52
0.57
0.57
0.57
2.23
2026
0.57
0.63
0.63
0.63
2.46
2027
0.63
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Daniel A. Carestio
Full Time Employees
17,937
Sector
Healthcare
Industry
Medical - Specialties
Address
5960 Heisley Road Mentor OH United States of America 44060
IPO Date
Jun 1, 1992
Website
steris.com
Business
STERIS plc (NYSE: STE), headquartered in Dublin, Ireland, with U.S. operational headquarters in Mentor, Ohio, is a leading global provider of infection prevention, contamination control, and procedural support products and services to healthcare, pharmaceutical, medical device, life sciences, and industrial customers in more than 100 countries. Founded in 1985 as Innovative Medical Technologies, the company offers capital equipment including steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers, automated washer/disinfectors, surgical tables, lights, booms, operating room integration systems, and automated endoscope reprocessors; consumables such as detergents, disinfectants, endoscopy accessories, barrier products, sterility assurance indicators, biological and chemical monitoring tools, sterilization pouches, and surgical instruments including V. Mueller, Snowden-Pencer, and Genesis brands; and services encompassing equipment installation and maintenance, instrument and scope repair, outsourced reprocessing, laboratory testing, contract sterilization via gamma irradiation, electron beam, ethylene oxide, and X-ray technologies, and gastrointestinal support solutions. STERIS operates through segments including Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies, targeting hospitals, surgery centers, medical device and pharmaceutical manufacturers, research facilities, and bioprocessing clients with a workforce exceeding 18,000 associates. Recent developments include the 2023 acquisition of Becton, Dickinson and Company's surgical instrumentation, laparoscopic, and sterilization container assets to expand healthcare offerings; facility expansions such as the 2025 openings of an ethylene oxide processing plant in Batu Kawan, Malaysia, and an X-ray processing addition in Suzhou, China; a 2024 business segment restructuring; and fiscal 2025 guidance projecting 8-9% revenue growth driven by consumables, services, and bioprocessing demand.

Company News

APIChatGPT
  • STERIS Q1 Earnings Call Highlights

  • STERIS Q1 Earnings Call Highlights

  • STERIS plc (STE) Q1 2027 Earnings Call Transcript

  • STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading

  • 5 Quality Stocks Set to Reward Investors With Dividend Hikes

  • Here's What Key Metrics Tell Us About Steris (STE) Q1 Earnings

  • Steris (STE) Q1 Earnings Surpass Estimates

  • STERIS Announces Financial Results for Fiscal 2027 First Quarter

  • Steris to invest $600 million in new North Carolina chemicals manufacturing hub

  • STERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina

  • STERIS Raises Dividend to $0.69 per share

  • STERIS' Q1 Earnings on Deck: What's in Store for the Stock?

  • STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026

  • Steris: A Good Moment To Buy Shares In This Sterilization Leader

  • Entropy Technologies LP Has $2.19 Million Holdings in STERIS plc $STE

  • STERIS plc $STE Shares Acquired by Arrowstreet Capital Limited Partnership

  • Why Steris (STE) is a Top Growth Stock for the Long-Term

  • Why Is Steris (STE) Up 1% Since Last Earnings Report?

  • Why Steris (STE) is a Top Momentum Stock for the Long-Term

  • Here's Why Steris (STE) is a Strong Growth Stock